Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

• Status: Recruiting
• Trial end date: 2026-01-21
• Target enrollment: 0
• Participant gender: All

Summary

Acute myeloid leukemia (AML) is a disease affecting older adults, although optimal strategies for treating such patients remain unclear. This prospective phase II, openlabel, multicenter study was designed to assess the efficacy and safety of two hematologic growth factors, recombinant human thrombopoietin (rhTPO) and granulocyte colonystimulating factor (G-CSF), in combination with decitabine, cytarabine, and aclarubicin (D-CTAG regimen) to treat older adults with newly diagnosed AML (Identifier: NCT04168138). The above agents were administered as follows: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000U daily, days 2, 4, 6, 8, 10-24 or until >50×109/L platelets); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9). We concurrently monitored historic controls treated with decitabine followed by cytarabine, aclarubicin, and G-CSF (D-CAG) only. After the first D-CTAG cycle, the overall response rate (ORR) was 84.2% (16/19), including 13 (73.7%) complete remissions (CRs) and three (15.8%) partial remissions. This CR rate surpassed that of the D-CAG treatment (p < 0.05). Median overall survival (OS) time in the D-CTAG group was 20.2 months (range, 4-31 months), compared with 14 months in the D-CAG group, and 1-year OS was 78%. The proportion of those experiencing grade III-IV thrombocytopenia was significantly lower for D-CTAG (57.9%) than for D-CAG (88.4%; p < 0.05). Ultimately, the curative effect of adding rhTPO was not inferior to that of D-CAG, and D-CTAG proved safer for elderly patients, especially in terms of hematologic toxicity. A prospective phase III randomized study is warranted to confirm these observations.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huihan Wang
• Treatments: Aclarubicin; Cytarabine; Decitabine

Criteria

Inclusion Criteria:

• Inclusion Criteria:

1. Age 60 or above, male or female;

2. Acute Myeloid Leukemia (non-M3) diagnosed according to the 2008 World Health Organization (WHO) diagnostic criteria for myeloid malignancies;

3. Newly diagnosed, no treatment for anti-leukemia;

4. The Eastern Cooperative Oncology Group（ECOG） status score is 0 to 3 points;

5. Expected survival time ≥ 3 months;

6. No serious heart, lung, liver or kidney disease;

7. History of no thromboembolism

8. Ability to understand and be willing to sign the informed consent form of this trial.

Exclusion Criteria:

Exclusion Criteria:

1. used to be allergic to the drugs contained in the protocol or to drugs similar in chemical structure to the test drugs;

2. serious active infections;

3. Patients with extramedullary lesions;

4. Patients who use drugs and long-term alcohol abuse to influence the evaluation of test results;

5. Inability to obtain informed consent and cannot complete the trial treatment and examination procedures because of mental illness or other conditions

6. Patients with clinically significant corrected QT interval (QTc) prolongation (male > 450ms, female > 470ms), Ventricular Tachycardia (VT), Atrial Fibrillation (AF), grade II or higher heart block, Myocardial Infarction (MI) within 1 year, Congestive Heart Failure (CHF), coronary heart disease with symptoms who need medical treatment;

7. Abnormal liver function (total bilirubin > 1.5 times the upper limit of normal value, Alanine aminotransferase(ALT) / Aspartate aminotransferase (AST) >2.5 times the upper limit of normal value or ALT / AST in patients with liver invasion > 5 times the upper limit of normal value of normal), abnormal renal function (serum Creatinine > 1.5 times the upper limit of normal);

8. The investigator determine that the participants are not suitable